<DOC>
	<DOCNO>NCT00278525</DOCNO>
	<brief_summary>Scleroderma systemic disorder categorize immunologically mediate disease cause collagen deposition skin visceral organ . The molecular pathogenesis scleroderma elusive , although vasculopathy immune mediate mechanism think important . Once extensive cutaneous visceral disease occur , prognosis significantly shorter general population . Although various treatment try , none seem change natural history scleroderma . Standard dose immunosuppressive treatment disappointing . Recently , cyclophosphamide 1-2 mg/kg/day orally 800-1400 mg intravenous ( IV ) monthly 6-9 month proven effective treatment scleroderma alveolitis ( 1 ) . Recent phase I study immunoablation autologous peripheral blood stem cell transplantation ( PBSCT ) show promising data , exact efficacy undetermined ( 2,3 ) . We propose , phase II randomize study , autologous unmanipulated PBSCT versus pulse cyclophosphamide patient systemic scleroderma .</brief_summary>
	<brief_title>Cyclophosphamide rATG With Hematopoietic Stem Cell Support Systemic Scleroderma</brief_title>
	<detailed_description>To evaluate efficacy two treatment modality : pulse cyclophosphamide versus high dose cyclophosphamide anti-thymocyte globulin ( ATG ) rescue autologous peripheral blood stem cell transplantation ( PBSCT ) . The primary endpoint consider study : I ) Time Treatment Failure -Treatment failure occur minimum 12 month enrollment time failure define : 1 . Failure skin score ( &gt; 14 enrollment ) improve increase skin score 25 % low post treatment value must document 2 occasion 6 month apart 2 . Deterioration diffuse capacity lung carbon monoxide ( DLCO ) , diffuse capacity divide alveolar volume ( DLCO/VA ) force vital capacity ( FVC ) 10 % enrollment level 10 % best post treatment value , due systemic sclerosis , document 2 occasion 6 month apart 3 . Renal failure due systemic sclerosis define chronic dialysis 12 month 4 . Gastrointestinal failure due systemic sclerosis define initiation total parenteral nutrition ( TPN ) 12 month II ) Disease improvement define least 25 % improvement skin score ( Rodnan ) , 10 % improvement pulmonary function test ( DLCO , DLCO/VA , FVC ) , cardiac test [ pulmonary artery ( PA ) systolic pressure right heart cath ) persist &gt; 6 month ability wean TPN</detailed_description>
	<mesh_term>Scleroderma , Systemic</mesh_term>
	<mesh_term>Scleroderma , Diffuse</mesh_term>
	<mesh_term>Scleroderma , Localized</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<criteria>Age 60 year &lt; 60 year old time pretransplant evaluation . An establish diagnosis scleroderma . Diffuse cutaneous scleroderma involvement proximal elbow knee Rodnan score &gt; 14 AND Scleroderma one following : Diffusing capacity lung carbon monoxide ( DLCO ) &lt; 80 % predict decrease lung function [ DLCO , diffuse capacity divide alveolar volume ( DLCO/VA ) force vital capacity ( FVC ) ] 10 % 12 month . Active alveolitis bronchoalveolar lavage . Pulmonary fibrosis alveolitis compute tomography ( CT ) scan chest xray ( CXR ) ( ground glass appearance alveolitis ) . Renal disease explain bacterial infection renal disorder . ( Subjects must two follow : proteinuria great trace dipstick , hematuria urine blood dipstick sediment , hypertension require treatment antihypertensive medication untreated diastolic blood pressure ( BP ) &gt; 95 mm/hg . ) Abnormal electrocardiogram ( EKG ) ( nonspecific STT wave abnormality , low QRS voltage , ventricular hypertrophy ) , pericardial effusion pericardial enhancement magnetic resonance imaging ( MRI ) Gastrointestinal tract involvement confirm radiological study . Radiologic finding scleroderma small bowel radiograph show thickened fold dilate loop , segmentation , flocculation +/ diverticulae , pseudodiverticulae . A hidebound appearance due valvulae pack i.e . dilate crowd circular fold , may present . Gastrointestinal ( GI ) involvement may also confirm Dxylose malabsorption , patulous esophagus , esophageal manometry . OR As publish NEJM , 2006 , 345:25 26552709 . Limited diffuse SSL lung involvement define active alveolitis bronchoalveolar lavage ( BAL ) groundglass opacity CT , DLCO &lt; 80 % predict decrease lung function ( DLCO/VA , DLCO , FVC ) 10 % last 12 month . Poor performance status Eastern Cooperative Oncology Group ( ECOG 2 ) time entry . Significant end organ damage : 1 . Left Ventricular Ejection Fraction ( LVEF ) &lt; 40 % deterioration LVEF exercise test Multiple Gated Acquisition ( MUGA ) echocardiogram . 2 . Untreated lifethreatening arrhythmia . 3 . Active ischemic heart disease heart failure . 4 . Endstage lung disease characterize total lung capacity ( TLC ) &lt; 45 % predict value . 5 . Pulmonary hypertension ( systolic pulmonary arterial pressure &gt; 40 mmHg mean pulmonary arterial pressure ( PAP ) &gt; 25 mmHG measurement pulmonary arterial catheter ) . 6 . Serum creatinine &gt; 2.0 mg/dl . 7 . Liver cirrhosis , transaminases &gt; 3x normal limit bilirubin &gt; 2.0 unless due Gilberts disease . 8 . Pericardial effusion &gt; 200ml unless successful pericardiocentesis 9 . Tricuspid annular peak systolic excursion ( TAPSE ) â‰¤ 1.9 cm 10 . MRI heart show D sign ( intraventricular flattering ) Human immunodeficiency virus ( HIV ) positive . Uncontrolled diabetes mellitus , illness opinion investigator would jeopardize ability patient tolerate aggressive treatment . Prior history malignancy except localize basal cell squamous skin cancer . Other malignancy patient judge cured local surgical therapy , ( limit ) head neck cancer , stage I II breast cancer consider individual basis . Positive pregnancy test , inability unable pursue effective mean birth control , failure willingly accept comprehend irreversible sterility side effect therapy . Psychiatric illness mental deficiency make compliance treatment inform consent impossible . Inability give inform consent . Major hematological abnormality platelet count &lt; 100,000/ul absolute neutrophil count ( ANC ) &lt; 1000/ul . Patients duration disease &gt; 5 year . Exclude &gt; 6 prior monthly IV cyclophosphamide treatment .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>March 2014</verification_date>
</DOC>